With 2.2 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.27 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $8.83 whereas the lowest price it dropped to was $7.97. The 52-week range on MNMD shows that it touched its highest point at $12.22 and its lowest point at $3.49 during that stretch. It currently has a 1-year price target of $25.89. Beta for the stock currently stands at 1.70.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MNMD was up-trending over the past week, with a rise of 21.04%, but this was up by 14.06% over a month. Three-month performance surged to 54.48% while six-month performance rose 14.23%. The stock gained 98.29% in the past year, while it has gained 16.52% so far this year. A look at the trailing 12-month EPS for MNMD yields -2.09 with Next year EPS estimates of -1.44. For the next quarter, that number is -0.29. This implies an EPS growth rate of 40.57% for this year and 0.48% for next year.
Float and Shares Shorts:
At present, 81.59 million MNMD shares are outstanding with a float of 27.23 million shares on hand for trading. On 2024-12-13, short shares totaled 9.44 million, which was 1288.0 higher than short shares on 1731628800. In addition to Mr. Robert Barrow as the firm’s CEO & Director, Dr. Daniel Rollings Karlin M.A., M.D. serves as its Chief Medical Officer.
Institutional Ownership:
Through their ownership of 0.68171996 of MNMD’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, MNMD reported revenue of $0.0 and operating income of -$24792000.0. The EBITDA in the recently reported quarter was -$21285000.0 and diluted EPS was -$0.27.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MNMD since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With MNMD analysts setting a high price target of 55.0 and a low target of 16.0, the average target price over the next 12 months is 25.88889. Based on these targets, MNMD could surge 578.18% to reach the target high and rise by 97.29% to reach the target low. Reaching the average price target will result in a growth of 219.22% from current levels.
Analysts have provided yearly estimates in a range of -$1.28889 being high and -$1.60037 being low. For MNMD, this leads to a yearly average estimate of -$1.45. Based on analyst estimates, the high estimate for the next quarter is -$0.31 and the low estimate is -$0.36. The average estimate for the next quarter is thus -$0.34.
